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occurred in 57.1% of mortality cases, followed by sepsis/septicemia (39.3%), coagu-
lopathies (23.8%), renal failure (19.4%) wasting syndrome/weight loss (18.4%), liver
disease (16.2%) heart failure (9.7%), lymphoma (6.6%), metastatic cancer (3.3%),
pulmonary circulation disorders (2.9%), and solid tumors (2.8%). Regression analy-
ses found that increased mortality and charges were associated with each afore-
mentioned comorbidity except wasting syndromes/weight loss. Significant
(p0.05) odds ratios were observed for inpatient mortality ranging from 1.17 (renal
failure) to 8.06 (sepsis/septicemia) and exponentiated beta-coefficients for charges
ranging from 1.03 (liver disease) to 1.33 (sepsis/septicemia). Various cancers were
associated with substantially worse outcomes. CONCLUSIONS: An increased un-
derstanding of severe comorbidities inHIV/AIDS is of continued importancewithin
hospital settings. Sepsis/septicemia and cancer is particularly associated with in-
creased inpatient mortality and charges.
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OBJECTIVES: Systematically review all randomized trials evaluating licensed rota-
virus vaccines for efficacy and safety on diarrhoea, hospital admission, death and
serious adverse events.METHODS: Electronic searches strategies were performed
until October 2011. Trial eligibility, data extraction and quality assessment were
performed independently by two reviewers. Dichotomous data were pooled using
the risk ratio (RR) and 95% CI. GRADE was used to evaluate evidence quality.
RESULTS: Forty-three RCTs including 190,551 participants were identified; 31 trials
assessed RV1, and 12 RV5. In children  1 year, RV1 (RR0.20, 95%CI0.11 to 0.35; 7
trials, 35,004 participants) and RV5 (RR0.23, 95%CI 0.08 to 0.71; 3 trials, 6953 par-
ticipants) are highly efficacious against severe rotavirus diarrhoea cases and/or
rotavirus diarrhea requiring hospitalization. For all-cause diarrhea, RV1 reduces
severe cases by 42% (RR0.58, 95% CI 0.40 - 0.84; 8291 participants), and RV5 by 72%
(RR0.28, 95%CI 0.16 - 0.48). Both vaccines were also efficacious during the second
year of life (RV1: RR0.16, 95%CI 0.12 - 0.21; 8 trials, 32,854 participants; RV5:
RR0.44, 95%CI 0.22 - 0.88; 4 trials, 9783 participants). For all-cause diarrhoea, RV1
reduces severe cases by 51% (RR0.49, 95%CI 0.40 - 0.60; 2 trials, 6269 participants).
Both vaccines had no impact on mortality, but serious adverse events following
vaccination, including intussusception, were not more common than following
placebo. CONCLUSIONS: RV1 and RV5 vaccines are efficacious and relatively safe.
These data support the WHO’s global vaccine recommendation. Potential reduced
vaccine efficacy in low income countries needs to be addressed. Ongoing safety
monitoring should be continued in countries that have introduced rotavirus vac-
cination.
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OBJECTIVES: MRSA-B is associated with high morbidity and cost. Guidelines rec-
ommend alternative treatment when VAN MICs are 2. DAP effectiveness in
MRSA-B patients (pts)with elevatedVANMICs is an important real-world question.
This analysis evaluates outcomes relevant to pts and institutions including clinical
success, DAP-related length of stay (LOS), and infection-related readmission.
METHODS: All pts with MRSA-B were identified in CORE 2010, a retrospective,
multicenter, observational registry of staphylococcal bacteremia pts with VAN
MIC2 mg/L per local lab. Investigators assessed pt outcome (cured, improved,
failed, nonevaluable) at the end or at last contact of DAP therapy. Pt characteristics
and outcomes are based on the efficacy population. All pts were included in the
safety analysis. RESULTS: A total of 158 pts with MRSA-B were identified; 142 had
initial VANMIC2 and were evaluable for outcome: 47%male, 40%65 years, 27%
CrCl 30mL/min, 21% on dialysis, 22% treated in the ICU. Frequent concurrent
infections included skin and skin structure (12%), endocarditis (9%), bone/joint
(8%). Median (min,max) DAP dose and duration were 6 mg/kg (4,11) and 13.5 days
(2,62), respectively. 80% (114/142) received prior antibiotics; (88% of which was
VAN). Success occurred in 89% overall, with no difference between first (89% [25/
28]) and second-line (89% [101/114]) DAP treatment. Time to clinical response
ranged from 1-27 days (median2). Median (min,max) DAP-related LOS was 9 days
(2,44). 21 pts (15%) were evaluated in the ER within 60 days of completing DAP
therapy. Infection-related readmission occurred in 10 pts (7%). 7 pts experienced 9
AEs possibly related to DAP; 5 pts discontinued DAP due to AE. Overall mortality
rate was 12%; 4 pts died within 7 days. CONCLUSIONS: This evaluation of real-
world effectiveness demonstrates that DAP may be a useful agent for MRSA-B
isolates with a VAN MIC2. Additional comparative effectiveness and resource
utilization studies are warranted.
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OBJECTIVES: The objective was to evaluate the efficacy and safety of the combina-
tion TDF/FTCEFV compared to the available treatment combinations in Mexico.
METHODS: We conducted a systematic review using the Cochrane guidelines of
randomized clinical trials in PUBMED,EMBASE, LILACS ANDARTEMISA to compare
TDF/FTCEFV, ABC/3TCEFV, ZDV/3TCEFV, LPV/rTDF/FTC and LPV/rABC/
3TC in naïve adult patients with HIV-1 infection. Themain outcome variables were
RNA HIV-1 copies less than 50/mm3 at 48 and 96 weeks, and grade 2-4 adverse
effects at 48 effects. We used a random model effects for the pooled analysis.
RESULTS:We included 6 articles, 4 at 48 weeks and 2 at 96 weeks. The arms were
grouped by the tree elements of HAART. The combination TDF/FTCEFV was the
most frequently used (3 studies). At 48 and 96 weeks the pooled probabilities to
have 50 RNA copies/ml for TDF/FTCEFVwere 0.771 (CI95% 0.711 – 0.821; n681)
and 0.670 (CI95% 0.607 – 0.727; n232); ZDV/3TCEFV 0.704 (CI95% 0.643 – 0.758;
n243) and 0.610(CI95% 0.546 – 0.671; n231); LPV/rABC/3TC 0.680 (CI95% 0.629 –
0.727; n343) and 0.600(CI95% 0.527 – 0.631; n343); ABC/3TCEFV 0.677 (CI95%
0.509 – 0.809; n437); and LPV/rTDF/FTC 0.670 (CI95% 0.619 – 0.718; n345) and
0.580(CI95% 0.527 – 0.631; n345) respectively. The adverse events rates (hypersen-
sitivity and diarrhea) at 48 weeks were for TDF/FTCEFV 0.005 (CI95% 0.001 – 0.036)
and 0.050 (CI 95% 0.017-0.136) respectively, TDF/FTCEFV show fewer adverse
events than compared to the other treatment regimens (LPV/rTDF/FTC, ABC/
3TCEFV and LPV/rABC/3TC ). At 48 weeks the discontinuation rate for EFV 
ZDV/3TCwas 0.91,( n254) and for LPV/r TDF/FTC 0.041 (n170). CONCLUSIONS:
The combination TDF/FTCEFV is themost studied combination and it is clinically
effective at 48 and 96 weeks, with good safety profile.
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OBJECTIVES: Chronic Hepatitis C virus (HCV) infection is one of the silent global
epidemics with significant unmet need and disease burden. One of the major lim-
itations of current treatments is the need for 12 or 6 months of Interferon based
therapy, which has tolerability and toxicity issues for many patients. During last
2-3 years several new agents have been tested in clinic, which have shown prom-
ising results as non-interferon based therapy. Goal of this study was to review the
clinical efficacy and safety profile of non-interferon based therapies for HCV
treatment.METHODS:We searched the MEDLINE, and abstracts from AASLD and
EASL until May 2011. Studies were selected for clinical trials on direct acting agents
for HCV. Primary endpoints reviewed were Sustained Viral Response (SVR). Toxic-
itywas evaluated as secondary endpoint. Aggregated datawere further analyzed to
understand comparative safety and efficacy. RESULTS: Until May 2011, results of
five eligible HCV clinical trials for interferon free regimens were available. Overall,
treatment with combination of protease and polymerase inhibitor showed dra-
matic viral load reduction after 2 weeks of treatment. The combination of PSI-7977
and PSI-938 showed 93% viral clearance after 14 days (n16). The combination of
RG7227 andRG7128 demonstrated 5.1 log reduction in viral load in treatment naive,
and 4.9 log reduction in null responder patients after 14 days of treatment. The
combination of BMS-790052 and BMS 650032 showed 36.3% 24 week SVR in null
responder patients. One study evaluating VX-222 and Telaprevir combination was
discontinued due to viral breakthrough. Several studies are currently on-going
whose data would be available in 2011-2012. CONCLUSIONS:Non-interferon based
therapies have shown impressive viral load reduction in short term studies. How-
ever, more data for SVR, viral breakthrough and resistance is needed to confirm
their safe use in HCV infected population.
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OBJECTIVES: To assess the clinical and economic burden of the human immuno-
deficiency virus (HIV) in the US veteran population. METHODS: A retrospective
study including patients diagnosed with HIV between October 1, 2005 and Septem-
ber 30, 2010 was conducted using the Veterans Health Affairs Medical SAS Data-
sets. Health care resource utilization and costs were assessed in the 12-month
follow-up period. Patients’ demographic, clinical and discharge statuseswere com-
pared using Chi-square testing and standardized differences. Student t-tests were
used for the means of continuous variables. Mortality and survival rates were
calculated using the Kaplan and Meier method and the PROC LIFETEST procedure.
RESULTS:Among all study patients diagnosedwith HIV (n29,388), mortality rates
in the 12-month follow-up period were 15.79% (n4,635), and 5.15% for patients
under age 40, 16.25% for patients age 40 to 65, and 30.01% for patients age 65 and
over. The most commonly prescribed medications were emtricitabine/tenofovir
(2.39%), efavirenz (2.34%), sulfamethoxazole/trimethopri (1.88%), lamivudine/zid-
ovudine (1.81%), lopinavir/ritonavir (1.76%), and atazanavir (1.68%). Themost com-
monly performed laboratory tests were for sodium (3.38%), potassium (3.27%), cre-
atinine (3.25%), chloride (3.25%), glucose quant (3.18%), and carbon dioxide content
(2.94%). For patients with HIV, the average numbers of inpatient (0.48), emergency
room (ER) (0.82), physician office (35.31) and outpatient visits (35.56) were calcu-
lated per patient, separately. The percentages of inpatient (24.62%), ER (35.01%),
physician office (99.90%) and outpatient visits (99.93%) were also computed, which
led to the following costs for inpatient ($7,828), ER ($329), physician office ($14,080)
and outpatient visits ($14,450). CONCLUSIONS: This study found that emtricit-
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